bisoprolol / Generic mfg. - LARVOL DELTA

One- and two-year structural changes of mavacamten therapy in hypertrophic obstructive cardiomyopathy: a case report with serial comprehensive CMR demonstrating continuous reverse remodelling. (PubMed, Eur Heart J Case Rep) - "A 39-year-old male with symptomatic HOCM refractory to bisoprolol and disopyramide was initiated on mavacamten therapy. This case indicates that mavacamten leads to longer-term cardiac remodelling up to two years after initiation of treatment, beyond early haemodynamic improvement and reduction of LVOT obstruction. These observations nurture additional studies to investigate longer-term effects on myocardial structure, function, and interstitial fibrosis."

Journal • Cardiomyopathy • Cardiovascular • Fibrosis • Hypertrophic Cardiomyopathy • Immunology • Obstructive Hypertrophic Cardiomyopathy

TAKO MEMRI: Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy (clinicaltrials.gov) - P=N/A | N=100 | Recruiting | Sponsor: University of Edinburgh

New trial • Cardiomyopathy • Cardiovascular

The Common Beta Blocker: A Cause of Non-Melanoma and Melanoma Skin Cancer? (AAD 2026) - " We conducted a retrospective cohort study using the TriNetX Research Network, including AF patients prescribed carvedilol, metoprolol, atenolol, bisoprolol, or nebivolol. Beta-blocker use does not appear broadly associated with cutaneous malignancy risk in AF patients; however, metoprolol may uniquely influence BCC and SCC risk. Further prospective studies are warranted to clarify agent-specific dermatologic safety profiles."

Atrial Fibrillation • Basal Cell Carcinoma • Genetic Disorders • Melanoma • Non-melanoma Skin Cancer • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma

FDG-PET GUIDED DIAGNOSIS AND MANAGEMENT OF CARDIAC SARCOIDOSIS DESPITE NEGATIVE MRI AND BIOPSY (ACC 2026) - "After multidisciplinary discussion, high-dose prednisone was started, later transitioned to mycophenolate mofetil (MMF) for steroid-sparing therapy...She remained stable on guideline-directed therapy including bisoprolol, sacubitril/valsartan, empagliflozin, spironolactone, and MMF... When MRI and biopsy are nondiagnostic, FDG-PET can provide critical diagnostic and therapeutic guidance in CS, facilitating immunosuppression, monitoring of response, and prevention of adverse outcomes through device therapy."

Biopsy • FDG PET • Cardiomyopathy • Cardiovascular • CNS Disorders • Congestive Heart Failure • Fibrosis • Heart Failure • Immunology • Inflammation • Pulmonary Disease • Sarcoidosis

SGLT2 INHIBITORS IN HYPERTROPHIC CARDIOMYOPATHY: LESSONS FROM A CLINICAL CASE (ACC 2026) - "Treatment with bisoprolol and empagliflozin was started. This case highlights clinical and paraclinical improvement with iSGLT2 in apical HCM, suggesting a promising therapeutic avenue."

Clinical • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertrophic Cardiomyopathy • Pulmonary Disease

COMPARISON OF BETA BLOCKER ADHERENCE BETWEEN ONCE VS TWICE A DAY DOSING REGIMENS IN PATIENTS HEART FAILURE WITH REDUCED EJECTION FRACTION (ACC 2026) - " Among 2,699 patients (mean age 66 years, 35% female, 38% White), 1952 (72%) were discharged on twice daily BBs (88% carvedilol, 9% bisoprolol, and 3% metoprolol succinate). Once versus twice daily BB was not associated with a significant difference in achieving PDC ≥80% at one year. These findings suggest that dosing frequency alone may not significantly influence GDMT BB adherence and other factors such as BB selectivity may play a more prominent role."

Adherence • Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure

CHALLENGING THE PARADIGM: EARLY RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITION WITH MECHANICAL CIRCULATORY SUPPORT PROMOTES DUAL ORGAN RECOVERY IN SEVERE CARDIORENAL SYNDROME, A CASE REPORT (ACC 2026) - "Once compensated, he was treated with milrinone and started on valsartan and spironolactone as part of his Impella weaning strategy...He was optimized with the addition of bisoprolol and empagliflozin... In select patients, MCS can create a stable hemodynamic bridge, enabling the safe and early initiation of RAAS inhibitors despite renal compromise from shock. This approach challenges the conventional practice of withholding these agents in cardiogenic shock-related AKI, offering a strategy to break the cardiorenal cycle and promote dual organ recovery"

Case report • Clinical • Acute Kidney Injury • Cardiovascular • Nephrology

WALKING INTO SUDDEN DEATH: BECKER'S MUSCULAR DYSTROPHY AND THE HIDDEN BURDEN OF SEVERE LEFT VENTRICULAR DYSFUNCTION (ACC 2026) - "Decision-Making: The patient was started on guideline directed medical therapy (GDMT); sacubitril/valsartan, bisoprolol, furosemide, spironolactone, and dapagliflozin. This case highlights the aggressive cardiac involvement in BMD. Myocardial fibrosis, along with severe systolic dysfunction, creates a substrate for malignant arrhythmias in these patients. As in this case, patients may remain ambulatory despite advanced cardiac disease, illustrating discordance between myocardial and skeletal dysfunction."

Becker Muscular Dystrophy • Cardiomyopathy • Cardiovascular • Duchenne Muscular Dystrophy • Fibrosis • Heart Failure • Immunology • Muscular Dystrophy • Myositis • Pulmonary Disease

CARDIOGENIC SHOCK INDUCED BY ANABOLIC STEROID USE IN A PATIENT WITH HEART FAILURE WITH PREVIOUSLY RECOVERED EJECTION FRACTION (ACC 2026) - "Genetic testing demonstrated uncertain significance variants in the DMD and TTN genes.After initiation of Guideline-Directed Medical Therapy (GDMT), including sacubitril/valsartan, bisoprolol, spironolactone, and dapagliflozin, the patient's LVEF improved to 66%, allowing him to resume his activities as a bodybuilder instructor...Decision-Making: The patient developed rapidly progressive respiratory failure and hypoperfusion despite the initiation of milrinone, and was being evaluated as cardiogenic shock stage C of the Society for Cardiovascular Angiography and Interventions (SCAI), so was connected to peripheral VA-ECMO, presenting severe bleeding associated with the femoral arterial access, which was challenging to canulate due to severe stiffness of the vessel... Relapse of heart failure in anabolic steroid users can occur due to multiple injuries to the cardiac myocyte, including direct cellular injury, fibrosis, and endothelial dysfunction. Patients typically..."

Clinical • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Fibrosis • Gastroenterology • Glomerulonephritis • Heart Failure • Hepatology • Immunology • Liver Cirrhosis • Pulmonary Disease • Respiratory Diseases • TTN

DENGUE-ASSOCIATED MYOCARDITIS WITH APICAL THROMBUS IN A 28-YEAR-OLD PATIENT PROGRESSING TO HEART TRANSPLANTATION DESPITE OPTIMIZED MEDICAL THERAPY: A CASE REPORT (ACC 2026) - "Initial therapy included enalapril 10 mg BID, bisoprolol 2.5 mg daily, spironolactone 25 mg daily, and furosemide 40 mg BID...Decision-Making: Medical therapy for HFrEF was optimized with sacubitril/valsartan 100 mg BID, empagliflozin 10 mg, spironolactone 50 mg and bisoprolol 5 mg BID. Repeat echocardiography showed persistent severe dysfunction and notable apical thrombus (15 x 8 mm), and rivaroxaban 20 mg daily was initiated... Dengue-associated myocarditis, though rare, may progress to severe cardiomyopathy and advanced heart failure. This case underscores the need for vigilance in patients with dengue presenting with cardiac symptoms and highlights the role of early advanced therapy referral, including heart transplantation, when standard management fails."

Case report • Clinical • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Dengue Fever • Heart Failure • Inflammation • Pulmonary Disease • Thrombosis • Transplantation

THE PARADOX OF THE LOW-RISK HEART A SUDDEN DEATH (ACC 2026) - "Amiodarone, bisoprolol, and anticoagulation were initiated, with a planned atrial fibrillation ablation at follow-up. This case emphasizes that ApHCM is not always benign. Despite a calculated SCD risk score below the conventional prophylactic threshold, the presence of myocardial fibrosis and conduction abnormalities may unmask a high-risk substrate requiring tailored management."

Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Fibrosis • Hypertrophic Cardiomyopathy • Immunology

DOES NEBIVOLOL FIT IN THE HEART FAILURE WITH PRESERVED/MIDRANGE EJECTION FRACTION TREATMENT ALGORITHM? INSIGHTS FROM NETWORK META-ANALYSIS (ACC 2026) - "A PRISMA-based search identified six trials involving Nebivolol, Bisoprolol, Atenolol, Carvedilol, and placebo. Nebivolol demonstrates a favorable efficacy profile in improving symptoms, function, and potentially reducing events in HFpEF/HFmrEF. These findings suggest that when β-blockade is indicated, Nebivolol may be the preferred choice. Further large-scale, phenotype-stratified trials are needed to define the role of Nebivolol in HFpEF management."

Retrospective data • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure • Hypertension

Probable digoxin-induced thrombocytopenia in an elderly haemodialysis patient: diagnostic rescue following drug withdrawal (UKKW 2026) - "Digoxin and bisoprolol were discontinued, with ongoing haemodialysis and cardiac monitoring. Implication In DD-CKD patients with abrupt thrombocytopenia, clinicians should review medications and consider digoxin toxicity before initiating ITP-directed therapies. Next step Systematic pharmacovigilance reporting, targeted platelet monitoring in high-risk digoxin users, and regular digoxin level checks in dialysis populations are warranted to reduce avoidable investigations and inform future nephrology–cardiology guideline updates."

Clinical • Atrial Fibrillation • Cardiovascular • Chronic Kidney Disease • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Infectious Disease • Nephrology • Renal Disease • Septic Shock • Thrombocytopenia • Thrombocytopenic Purpura • CRP

Cardioprotection in patients with anthracycline-treated breast cancer: final analysis from the 2 × 2 randomized, placebo-controlled, double-blind SAFE trial. (PubMed, ESMO Open) - "Ramipril and bisoprolol significantly reduce the incidence of subclinical cardiac damage in patients with breast cancer undergoing anthracycline-based chemotherapy, thus supporting their use as early prevention cardioprotective strategies."

Journal • Breast Cancer • Cardiovascular • Oncology • Solid Tumor

Systemic medications associate with surgically treated cataract among adults over 50 years in Finland. (PubMed, Acta Ophthalmol) - "Our large nested case-control study suggests that certain systemic medications may increase the incidence of surgically treated cataract, but with the possibility of residual confounding."

Journal • Cataract • Diabetes • Metabolic Disorders • Ophthalmology

Acute effects of low-dose bisoprolol on lung function and blood pressure in COPD patients. (PubMed, ERJ Open Res) - "There was no significant difference in FEV1 (L) or SBP at baseline At 120 min the intolerant group's mean FEV1 had significantly decreased to 1.05 L (95% CI 0.86-1.25 L; p95% of COPD patients."

Journal • Cardiovascular • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Unrepaired Truncus Arteriosus Type 1 With Eisenmenger Syndrome and Recurrent Embolic Strokes: An Adult Case Report. (PubMed, Am J Case Rep) - "A conservative management strategy was adopted, including dual antiplatelet therapy, sildenafil, macitentan, bisoprolol, and oxygen therapy. CONCLUSIONS This case highlights the exceptional natural course of uncorrected truncus arteriosus in adulthood. It underscores that for patients with Eisenmenger physiology where surgical repair is not feasible, a multidisciplinary approach focusing on tailored antithrombotic and pulmonary vasodilator therapies is essential for stroke prevention and clinical stability."

Journal • Cardiovascular • Hypertension • Ischemic stroke • Otorhinolaryngology • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Vertigo

AIFA-CARDIO-129: Pharmacological optimization in prevention in Heart Failure: A Sex-gap? (clinicaltrialsregister.eu) - P4 | N=368 | Not yet recruiting | Sponsor: Policlinico San Donato S.p.A.

New P4 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

Sacubitril/valsartan facilitates recovery of cardiac function in a patient with peripartum cardiomyopathy: a case report. (PubMed, Eur Heart J Case Rep) - "After delivery, heart failure therapy with carvedilol, spironolactone, and furosemide was initiated, but carvedilol was discontinued due to hypotension...Although bisoprolol and empagliflozin were initiated, LVEF further dropped to 27%...This case highlights the complexity of PPCM management. Sacubitril/valsartan may serve as an effective therapeutic option for PPCM patients who are intolerant to conventional therapy."

Journal • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Gynecology • Heart Failure • Hypotension • Pulmonary Disease

Z-2025058: A trial investigating partial withdrawal of heart failure therapy in patients with heart failure in remission. (clinicaltrialsregister.eu) - P4 | N=100 | Not yet recruiting | Sponsor: Ziekenhuis Oost Limburg

New P4 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

A Prospective Clinical Audit to Improve Compliance With Perioperative Atrial Fibrillation Prevention Protocols in Off-Pump Coronary Artery Bypass Surgery. (PubMed, Cureus) - "Bisoprolol was the institutional beta-blocker; ivabradine was used if beta-blockers were contraindicated. Conclusion Structured, multidisciplinary quality-improvement measures significantly improved compliance with AF prevention protocols and were associated with a decrease in postoperative AF incidence by 50% in OPCAB patients. Routine audits and sustained adherence to protocol are recommended."

Compliance • Journal • Atrial Fibrillation • Cardiovascular

A novel method for rapid determination of risperidone in human plasma using Reversed-Phase Liquid Chromatography with Ultra-Violet detection. (PubMed, Tunis Med) - "The method shows good specificity with respect to commonly prescribed psychotropic drugs."

Journal

Beta-Blocker (Bisoprolol) vs Calcium-Channel Blocker (Verapamil) in Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Triple-Crossover Physiologic Trial. (PubMed, J Am Coll Cardiol) - "In nonobstructive HCM, treatment with bisoprolol reduced pVO2, whereas it was unchanged with verapamil. There were a number of significant differences in exercise response, structural changes, myocardial function, symptoms, and biomarkers. This study provides new insights into the mechanisms of these drugs that might be taken into consideration in management of nonobstructive HCM."

Clinical • Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy • Ventricular Tachycardia

TRENDS IN GUIDELINE-DIRECTED MEDICAL THERAPY AMONG PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (ISPOR 2026) - "GDMT consisted of an evidence-based β‑blocker (carvedilol/metoprolol succinate/bisoprolol); ACE inhibitor, ARB, or ARNI; MRA; and SGLT2i. Prescribing and dispensing of GDMT in patients with HFrEF improved during 2020-2024 but remained underutilized. Similar findings were observed with rapid initiation of GDMT. Greater effort is needed to ensure timely initiation of these therapies."

Clinical • Cardiovascular • Congestive Heart Failure • Genetic Disorders • Heart Failure • Obesity

Beyond Atrial Fibrillation: A Case of Thyrotoxicosis-Associated Ischemic Stroke in a Young Patient. (PubMed, Cureus) - "Postoperatively, she developed refractory fever, extreme tachycardia, and hypertension despite broad-spectrum antibiotics for presumed sepsis. Endocrine workup confirmed thyroid storm, and the patient was treated aggressively with propylthiouracil, cholestyramine, and bisoprolol in addition to stress-dose glucocorticoids. Subsequent labs uncovered refractory hypercalcemia, prompting further evaluation that confirmed hyperparathyroidism. Emerging evidence further implicates thyroid dysfunction in coagulation pathway dysregulation, which may predispose patients to thromboembolic events independent of cardiac arrhythmias. This case underscores the importance of considering thyrotoxicosis in cryptogenic stroke, even without AF, and highlights gaps in current guidelines regarding anticoagulation therapy for this high-risk population."

Journal • Atrial Fibrillation • Cardiovascular • Endocrine Disorders • Hematological Disorders • Hypertension • Infectious Disease • Ischemic stroke • Metabolic Disorders • Septic Shock • Vascular Neurology